Emerging evidence indicates that ion channels act in a variety of physiologic and pathologic processes beyond electronic signal transmission, including in cancer. We recently found that the potassium channel Eag1 can mediate cancer progression and that a monoclonal antibody, which inhibits Eag1 action, can effectively restrict cancer cell proliferation. We discuss how Eag1 targeting may be useful in diagnostic or therapeutic settings.